Host |
Mouse |
Klon |
57PO6 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b, κ |
Lokalisation |
Nucleus |
p57 (KIP2)
|
Diagnostic Biosystems |
57PO6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB291-05 |
-
|
Host |
Mouse |
Klon |
57PO6 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG2b, κ |
Lokalisation |
Nucleus |
p57 (KIP2)
|
Diagnostic Biosystems |
57PO6 |
6 ml |
Ready-to-use |
CE/IVD |
PDM205 |
-
|
Host |
Mouse |
Klon |
57PO6 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG2b, κ |
Lokalisation |
Nucleus |
p57 (KIP2)
|
Diagnostic Biosystems |
57PO6 |
25 ml |
Ready-to-use |
CE/IVD |
PDM205-25 |
-
|
Host |
Mouse |
Klon |
KP10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma or placenta. |
Verdünnung |
1:100 - 1:500 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human p57Kip2 protein |
Lokalisation |
Nucleus |
p57Kip2
|
Zeta Corporation |
KP10 |
1ml |
Concentrate |
CE/IVD |
Z2173ML |
-
|
Host |
Mouse |
Klon |
KP10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma or placenta. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human p57Kip2 protein |
Lokalisation |
Nucleus |
p57Kip2
|
Zeta Corporation |
KP10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2173MP |
-
|
Host |
Mouse |
Klon |
KP10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma or placenta. |
Verdünnung |
1:100 - 1:500 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human p57Kip2 protein |
Lokalisation |
Nucleus |
p57Kip2
|
Zeta Corporation |
KP10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2173MS |
-
|
Host |
Mouse |
Klon |
KP10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma or placenta. |
Verdünnung |
1:100 - 1:500 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human p57Kip2 protein |
Lokalisation |
Nucleus |
p57Kip2
|
Zeta Corporation |
KP10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2173MT |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal Prostate |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Nucleus |
p63
|
Zytomed Systems GmbH |
4A4 |
16 ml |
Ready-to-use |
RUO |
BMS052 |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
0.1 ml |
Concentrate |
CE/IVD |
CM163A |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
0.5 ml |
Concentrate |
CE/IVD |
CM163B |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
1 ml |
Concentrate |
CE/IVD |
CM163C |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
- |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
6 ml |
Ready-to-use |
CE/IVD |
PM163AA |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
- |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
25 ml |
Ready-to-use |
CE/IVD |
PM163H |
-
|
Host |
Rabbit |
Klon |
DBR16.1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate carcinoma, tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant human p63 protein fragment |
Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
1 ml |
Concentrate |
CE/IVD |
RMAB086 |
-
|
Host |
Rabbit |
Klon |
DBR16.1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate carcinoma, tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant human p63 protein fragment |
Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB086-01 |
-
|
Host |
Rabbit |
Klon |
DBR16.1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate carcinoma, tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant human p63 protein fragment |
Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB086-05 |
-
|
Host |
Rabbit |
Klon |
DBR16.1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate carcinoma, tonsil |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant human p63 protein fragment |
Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD086 |
-
|
Host |
Rabbit |
Klon |
DBR16.1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate carcinoma, tonsil |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant human p63 protein fragment |
Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
25 ml |
Ready-to-use |
CE/IVD |
RMPD086-25 |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
1.0 ml |
Concentrate |
RUO |
Z2003ML-R |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
7 ml |
Ready-to-use |
RUO |
Z2003MP-R |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
0.5 ml |
Concentrate |
RUO |
Z2003MS-R |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
0.1 ml |
Concentrate |
RUO |
Z2003MT-R |
-
|
Host |
Monospecific Mouse |
Klon |
ZM70 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin or prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human p63 protein |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
1 ml |
Concentrate |
CE/IVD |
Z2380ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM70 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin or prostate. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human p63 protein |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
7 ml |
Ready-to-use |
CE/IVD |
Z2380MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM70 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin or prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human p63 protein |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
0.5 ml |
Concentrate |
CE/IVD |
Z2380MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM70 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin or prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human p63 protein |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
0.1 ml |
Concentrate |
CE/IVD |
Z2380MT |
-
|
Host |
Mouse + Rabbit |
Klon |
4A4+EP42 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1+Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic |
p63 + Cytokeratin 5 (Lung Squamous-2 TM)
|
Biocare Medical |
4A4+EP42 |
6 ml |
Ready-to-use |
CE/IVD |
PM391DSAA |
-
|
Host |
Rabbit |
Klon |
ZR316 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Breast lobular carcinoma, melanom |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
1 ml |
Concentrate |
CE/IVD |
Z2620RL |
-
|
Host |
Rabbit |
Klon |
ZR316 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Breast lobular carcinoma, melanom |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
7 ml |
Ready-to-use |
CE/IVD |
Z2620RP |
-
|
Host |
Rabbit |
Klon |
ZR316 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Breast lobular carcinoma, melanom |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
0.5 ml |
Concentrate |
CE/IVD |
Z2620RS |
-
|
Host |
Rabbit |
Klon |
ZR316 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Breast lobular carcinoma, melanom |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
0.1 ml |
Concentrate |
CE/IVD |
Z2620RT |
-
|
Host |
Mouse + Rabbit |
Klon |
98/pp120 + EP6 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 + Rabbit IgG |
Lokalisation |
Cytoplasm (p120) and cell membrane (E-Cadherin) |
p120 + E-Cadherin (LC/DC Breast Cocktail)
|
Biocare Medical |
98/pp120 + EP6 |
6 ml |
Ready-to-use |
CE/IVD |
API3011DSAA |
-
|
Host |
Mouse |
Klon |
98/pp120 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
1:100 - 1:250 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
p120, Catenin (delta)
|
Biocare Medical |
98/pp120 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3008A |
-
|
Host |
Mouse |
Klon |
98/pp120 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
1:100 - 1:250 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nuclear |
p120, Catenin (delta)
|
Biocare Medical |
98/pp120 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3008B |
-
|
Host |
Mouse |
Klon |
98/pp120 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nuclear |
p120, Catenin (delta)
|
Biocare Medical |
98/pp120 |
6 ml |
Ready-to-use |
CE/IVD |
API3008AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit Ig |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
16 ml |
Ready-to-use |
RUO |
BRB035 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR046 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit Ig |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
6 ml |
Ready-to-use |
RUO |
RBG002 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit Ig |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
RBK002 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit Ig |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK002-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP134 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP134-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP134-05 |
-
|
Host |
Rabbit |
Klon |
13H4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
1:150 |
Isotyp |
IgG |
Verdünnung |
Human AMACR (P504S) polypeptide |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
1 ml |
Concentrate |
CE/IVD |
Z2001RL |
-
|
Host |
Rabbit |
Klon |
13H4 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Human AMACR (P504S) polypeptide |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
7 ml |
Ready-to-use |
CE/IVD |
Z2001RP |
-
|
Host |
Rabbit |
Klon |
13H4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
1:150 |
Isotyp |
IgG |
Verdünnung |
Human AMACR (P504S) polypeptide |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
0.5 ml |
Concentrate |
CE/IVD |
Z2001RS |
-
|
Host |
Rabbit |
Klon |
13H4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
1:150 |
Isotyp |
IgG |
Verdünnung |
Human AMACR (P504S) polypeptide |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
0.1 ml |
Concentrate |
CE/IVD |
Z2001RT |
-
|
Host |
Mouse + Rabbit |
Klon |
L26 + polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a & Rabbit Ig |
Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
16 ml |
Ready-to-use |
RUO |
BMS026 |
-
|
Host |
Mouse + Rabbit |
Klon |
L26 + polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Mouse IgG2a & Rabbit Ig |
Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
1 ml |
Concentrate |
RUO |
CO002K |
-
|
Host |
Mouse + Rabbit |
Klon |
L26 + polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Mouse IgG2a & Rabbit Ig |
Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
0.5 ml |
Concentrate |
RUO |
CO002K-05 |
-
|